TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: decrease in patient anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in education time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-AIDS deaths
Endpoint domain: Mortality/survival
Primary endpoint: Median Survival Time (MST)
Endpoint domain: Mortality/survival
Primary endpoint: Objective response at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zinc homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protection against P. falciparum infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean time to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to prostate-specific antigen doubling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT interval measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sST2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinfarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of normally perfused microvessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of pathologic hyper-dynamically perfused vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reproducibility of EMAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nGER score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in SNOT-22 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of rhinosinusitis symptoms on QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance or improvement in the photoreceptor layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to complete wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median epithelialized area of the ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vein occlusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cross-sectional area (CSA) at hip sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Z-score at hip sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of grade 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of VAS score at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VAS score on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diet quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: micronutrient intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency of utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores on formative tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed questionnaires returned
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total HDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol:HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exercise-induced increase in skeletal muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood draw to dosage calculation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinic systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinic diastolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 24 h ambulatory systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 24 h ambulatory diastolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BIIB023 pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of any stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of major coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: later carotid revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delivery of preventive asthma care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of onset of PTSD
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Active Dorsiflexion Range of Motion (ADFROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Dorsiflexion Range of Motion (PDFROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lunge Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL resistance to oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of the posterior cingulate cortex (PCC) during painful stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Opercular activation during painful stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Unhealthy Drinking (UHD) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titers (GMT) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection (HI antibody titers > or = 1:40 in > 70% of those vaccinated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of eye irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in FINDRISC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quality of wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: surgical times for screw placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: gains in accuracy on trained and untrained verbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative opioid usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extraction torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Multiple Sclerosis (MS)
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge of drug side effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of newly prescribed drugs unknown to the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BCQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Q‐TWiST gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of bone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg-pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacifier use in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA(1c) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time spent with SaO2<90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional performance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for volar block
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hard events (cardiac death or myocardial infarction)
Endpoint domain: Mortality/survival
Primary endpoint: total events (hard events or late myocardial revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: median percentage time for which gastric pH < 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recurrence-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Sensory neuropathy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life (PedsQL total score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immediate tumor response to RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rim blood flow increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar mucosa healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pool size of Lp(a)-apo(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of Lp(a)-apo(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional catabolism of Lp(a)-apo(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death from cardiovascular causes or hospitalization for HF
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of cryoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean sinus cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in IGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of incident ASCVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AF burden reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total time from arrival to discharge readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient preference for anaesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPO dose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia therapy costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chest pain severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in pruritus AUC (0, 72 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysplasia/cancer-free survival
Endpoint domain: Mortality/survival
Primary endpoint: bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net Flow Time (NFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean defect width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean defect height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall mean defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported confusion
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: carbohydrate craving
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: memory word recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: DT performance in the trained condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: curative and remarkably effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average IUC duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with IUC duration <3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uLTE4 excretion during EAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of LAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to AIDS/death
Endpoint domain: Mortality/survival
Primary endpoint: whole-brain MTI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DWI histogram parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: single-voxel MR spectroscopy measurements of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent FEV(1) decline from maximal values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in plasma DHEA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Unsuccessful first punctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hematomas observed
Endpoint domain: Adverse events/effects
Primary endpoint: bench press lifting volume (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bench press peak power (W)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients with gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients with positive yeast counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of BTB/BTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LV end-systolic volume index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality at six months
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of face-to-face visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of participants reporting positive change in quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean annual cost-saving
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of BMP-15 in follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of AMH after DHEA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accumulated score of embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycated hemoglobin (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Work-DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Menopause Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fatigue Severity Scale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 17beta‐estradiol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CaOx relative saturation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of entoptic perimetry for detection of central diabetic scotomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of entoptic perimetry for detection of CSME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate/severe OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of preventive interventions
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive deficits based on MMSE scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean VMS frequency per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hives (weekly average)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pruritus and size of largest hive (weekly average)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: St George's Respiratory Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: plasma apoA‐I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoA‐I production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effective renal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Body Fat (BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid profile (tCh, TL, LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leptin and adiponectin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse event incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy for correct condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief during grommet insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total plasma cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Haemoglobin A1c reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: physical symptom score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ophthalmoscopy training score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sudden cardiac death (SCD)
Endpoint domain: Mortality/survival
Primary endpoint: Intelligence Quotient (IQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR (Post-Void Residual)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qmax (Maximum Urinary Flow Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of the QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes